Bio-Rad Laboratories (NYSE:BIO – Get Free Report) issued its quarterly earnings data on Thursday. The medical research company reported $3.11 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.99, Briefing.com reports. The company had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.56%. Bio-Rad Laboratories’s revenue for the quarter was down 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.00 earnings per share. Bio-Rad Laboratories updated its FY 2024 guidance to EPS.
Bio-Rad Laboratories Price Performance
Shares of BIO traded down $5.32 on Friday, reaching $335.93. 448,637 shares of the company’s stock traded hands, compared to its average volume of 240,792. The stock’s 50 day simple moving average is $293.21 and its two-hundred day simple moving average is $307.72. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.89 and a current ratio of 6.57. Bio-Rad Laboratories has a 52-week low of $261.59 and a 52-week high of $419.00.
Insider Activity
In related news, EVP Michael Crowley sold 369 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $281.91, for a total transaction of $104,024.79. Following the completion of the sale, the executive vice president now owns 6,573 shares in the company, valued at $1,852,994.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 17.06% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on BIO
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
See Also
- Five stocks we like better than Bio-Rad Laboratories
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Pros And Cons Of Monthly Dividend Stocks
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Where to Find Earnings Call Transcripts
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.